Free Trial
CNSX:BUX

Biomark Diagnostics (BUX) Stock Price, News & Analysis

Biomark Diagnostics logo

About Biomark Diagnostics Stock (CNSX:BUX)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
11,500 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.

Receive BUX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomark Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

BUX Stock News Headlines

Forced out of retirement by these trades
You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed
See More Headlines

BUX Stock Analysis - Frequently Asked Questions

Shares of BUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biomark Diagnostics investors own include Stantec (STN) and IQE (IQE).

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (CNSX:BUX) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners